Details
Category: Volume 10 Issue 10 October 2022
Hits: 709

Title: Evaluation of Ocular Surface Disease in Patients on Topical Antiglaucoma Drugs

Authors: Dr Rakshan Reyaz MBBS, Dr Asif Amin Vakil MS, Dr Syed Sadaf Altaf MS, Dr Sabia Rashid MS, Dr Ifrah Davood MBBS

 DOI: https://dx.doi.org/10.18535/jmscr/v10i10.21

Abstract

Purpose: To evaluate Ocular Surface Disease in glaucoma patients using topical medications.

Material and Methods: A total of 108 eyes of 60 glaucoma patients who used topical antiglaucoma medications for a minimum period of 6 months were enrolled and followed up for a period of 1 year. Duration of therapy and drops/day were noted. Patients underwent complete ocular examination including Schirmer test, slit-lamp examination for tear film break-up time, and OSDI questionnaire.

Results: The mean age of the patients was 55 ± 11.84 yrs. Schirmer’s Test 1 at baseline had a mean value of 18.12 ± 6.98mm which decreased to a mean value of 13.40 ± 4.84mm at 1 year follow up. Schirmer’s Test 1 values worsened with increasing the number of daily drug instillations. Tearfilm Break Up Time (TBUT) had a baseline mean value of 16.01 ± 3.95 secs which decreased to a mean value of 13.06 ± 3.12 secs at 1 year follow up. TBUT values decreased with increasing the number of daily drops instilled. OSDI values increased with increasing the number of daily drops instilled.

Conclusion: OSD is common in treated glaucoma patients causing symptoms and signs that may hamper the patient’s quality of life. The symptoms worsen with increasing the number and frequency of drug instillation. The usage of preservative-free products, combination drug products, and concurrent use of lubricating eye drops may be helpful in alleviating the symptoms.

Keywords: Glaucoma, Ocular surface disease, OSDI, TBUT, Schirmers test.

References

  1. Shields Textbook of Glaucoma, 6th Edition by R.Rand Allingham, Karim F. Damji, Sharon Freedman, Sayoko E. Moroi, Douglas J.Rhee.
  2. Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN (2004) An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Archives of Ophthalmology 138, S19–S31.
  3. Goldberg I, Graham SL, Healey PR (2002) Primary open-angle glaucoma. The Medical Journal of Australia 177, 535–536.
  4. Quigley HA and Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267.
  5. Quigley HA. The number of persons with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389–93.
  6. Banomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna-Neumarkt Study. Ophthalmology 1998;105:209-215.
  7. Kanski’s Clinical Ophthalmology, 9th Edition by John F. Salmon
  8. Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging 2011;28:267–282.
  9. Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eyes Res. 2011;26391-398.
  10. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure lowering medications. Cornea 2010; 29:618–621.
  11. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012; 153:1–9.
  12. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to antiglaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 2003; 12:480–485.
  13. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341–349.
  14. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418–423.
  15. Barisic F, Krolo I, Popovic- Suic S, Sesar I, Simic- Prskalo M, et al. Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications. J Clin Exp Ophthalmol. 2014;5:334.
  16. Zane Anwara, Sarah R. Wellika, and Anat Galor. Glaucoma therapy and ocular surface disease:current literature and recommendations. Curr Opin Ophthalmol 2013 Mar;24(2):136-43
  17. Rasmussen CA, Kaufman PL, Kiland JA. Benzalkonium Chloride and Glaucoma. Journal of Ocular Pharmacology and Therapeutics. 2014;30:163- 169.
  18. Baudouin C, Renard JP, Nordmann JP, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol 2013; 23: 47–54.
  19. Cvenkel B, Stunf S, Srebotnik Kirbis I, Strojan Flezar . Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma. Clinical Ophthalmology. 2015;9:625-631.
  20. Leung EW, Medeiros FA and Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17: 350–355.
  21. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144:533–540.
  22. Wong ABC, Wang MTM, Liu K et al. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocul Surf. 2018;16(3):289-293.
  23. Dogan E, Cakir BK, Aksoy NO, Celik E, Erkorkmaz U. Effects of topical antiglaucomatous medications on central corneal epithelial thickness by anterior segment optical coherence tomography. Eur. J. Ophthalmol. 2020;30:1519–24.
  24. do Prado Baffa L, da Silva Ricardo JR, Carolina Dias A et al. Tear film and ocular surface alterations in chronic users of antiglaucoma medications. Arq Bras Oftalmol. 2008;71(1):18-21.
  25. E Wróblewska Schirmer test I and BUT (break-up-time) in patients treated with topical antiglaucoma drugs for a long time. Klin Oczna 1999;101(1):49-50.
  26. Ghosh S, O'Hare F, Lamoureux E, Vajpayee RB, Crowston JG. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012;40(7):675-81.
  27. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure lowering medications. Cornea 2010; 29:618–621.
  28. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572-579.
  29. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418–423.
  30. Kumar S, Singh T, Ichhpujani P et al. Correlation of Ocular Surface Disease and Quality of Life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost.  Turk J Ophthalmol 2020;50:75-81.

Corresponding Author

Dr Rakshan Reyaz

Postgraduate, Department of Ophthalmology, Government Medical College, Srinagar, J&K, India